Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H -chromene-3- carboxylate (CXL017) and its analogues

Journal of Medicinal Chemistry

Volumn 54, Issue 16, 2011, Pages 5937-5948

  Das, Sonia G ^a   Srinivasan, Balasubramanian ^a   Hermanson, David L ^a   Bleeker, Nicholas P ^a   Doshi, Jignesh M ^a   Tang, Ruoping ^b   Beck, William T ^c   Xing, Chengguo ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOXYLIC ACID DERIVATIVE; CHROMENE DERIVATIVE; CXL 017; ETHYL 2 AMINO 6 (3,5 DIMETHOXYPHENYL) 4 (2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLATE; MITOXANTRONE; PACLITAXEL; PROP 2 YN 1 YL 2 AMINO 6 (3,5 DIMETHOXYPHENYL) 4 [2 OXO 2 (PROP 2 YN 1 YLOXY)ETHYL] 4H CHROMENE 3 CARBOXYLATE; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN HL 60; CROSS RESISTANCE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; ENANTIOMER; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BENZOPYRANS; CELL LINE, TUMOR; CELL SURVIVAL; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HCT116 CELLS; HL-60 CELLS; HT29 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; MITOXANTRONE; MOLECULAR STRUCTURE; NEOPLASMS; PACLITAXEL; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VINCRISTINE;

EID: 80051896322     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200764t     Document Type: Article

References (26)

1. Kuendgen, A.; Germing, U. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly Cancer Treat. Rev. 2009, 35, 97-120
2. Lowenberg, B.; Downing, J. R.; Burnett, A. Acute myeloid leukemia N. Engl. J. Med. 1999, 341, 1051-1062 (Pubitemid 29451802)
3. Fanning, S. R.; Sekeres, M. A.; Theil, K. Accute Myelogenous Leukemia; The Cleveland Clinic Foundation: Cleveland, OH, 2009; http://www. clevelandclinicmeded.com/medicalpubs/diseasemanagement/hematology-oncology/ acute-myelogenous-leukemia/.
4. Lage, H. An overview of cancer multidrug resistance: a still unsolved problem Cell. Mol. Life Sci. 2008, 65, 3145-3167
5. Mellor, H. R.; Callaghan, R. Resistance to chemotherapy in cancer: a complex and integrated cellular response Pharmacology 2008, 81, 275-300 (Pubitemid 351666917)
6. Campos, L.; Rouault, J. P.; Sabido, O.; Oriol, P.; Roubi, N.; Vasselon, C.; Archimbaud, E.; Magaud, J. P.; Guyotat, D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy Blood 1993, 81, 3091-3096 (Pubitemid 23162130)
7. Elmore, S. Apoptosis: a review of programmed cell death Toxicol. Pathol. 2007, 35, 495-516 (Pubitemid 46911891)
8. Youle, R. J.; Strasser, A. The BCL-2 protein family: opposing activities that mediate cell death Nat. Rev. Mol. Cell Biol. 2008, 9, 47-59
9. Reed, J. C.; Miyashita, T.; Takayama, S.; Wang, H. G.; Sato, T.; Krajewski, S.; Aime-Sempe, C.; Bodrug, S.; Kitada, S.; Hanada, M. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy J. Cell. Biochem. 1996, 60, 23-32 (Pubitemid 26047917)
10. Reed, J. C. Bcl-2 family proteins Oncogene 1998, 17, 3225-3236 (Pubitemid 29043975)
11. Adams, J. M.; Cory, S. The Bcl-2 protein family: arbiters of cell survival Science 1998, 281, 1322-1326 (Pubitemid 28406819)
12. Kang, M. H.; Reynolds, C. P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy Clin. Cancer Res. 2009, 15, 1126-1132
13. Leber, B.; Geng, F.; Kale, J.; Andrews, D. W. Drugs targeting Bcl-2 family members as an emerging strategy in cancer Expert Rev. Mol. Med. 2010, 12 e28
14. Kang, M. H.; Reynolds, C. P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy Clin. Cancer Res. 2009, 15, 1126-1132
15. Lickliter, J. D.; Wood, N. J.; Johnson, L.; McHugh, G.; Tan, J.; Wood, F.; Cox, J.; Wickham, N. W. HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death Leukemia 2003, 17, 2074-2080 (Pubitemid 37428370)
16. Skommer, J.; Wlodkowic, D.; Matto, M.; Eray, M.; Pelkonen, J. HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells Leuk. Res. 2006, 30, 322-331 (Pubitemid 43053228)
17. Doshi, J. M.; Tian, D.; Xing, C. Ethyl-2-amino-6-bromo-4-(1-cyano-2- ethoxy-2-oxoethyl)-4 H -chromene-3-carboxylate (HA 14-1), a prototype small-molecule antagonist against antiapoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species that induce apoptosis Mol. Pharmaceutics 2007, 4, 919-928
18. Tian, D.; Das, S. G.; Doshi, J. M.; Peng, J.; Lin, J.; Xing, C. sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell Cancer Lett. 2008, 259, 198-208 (Pubitemid 350251643)
19. Hermanson, D.; Addo, S. N.; Bajer, A. A.; Marchant, J. S.; Das, S. G.; Srinivasan, B.; Al-Mousa, F.; Michelangeli, F.; Thomas, D. D.; Lebien, T. W.; Xing, C. Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria Mol. Pharmacol. 2009, 76, 667-678
20. Das, S. G.; Doshi, J. M.; Tian, D.; Addo, S. N.; Srinivasan, B.; Hermanson, D. L.; Xing, C. Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4 H -chromene-3-carboxylate (sha 14-1) and its analogues J. Med. Chem. 2009, 52, 5937-5949
21. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 1984, 22, 27-55
22. Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen Nat. Rev. Cancer 2006, 6, 813-823 (Pubitemid 44450469)
23. Naasani, I.; Seimiya, H.; Yamori, T.; Tsuruo, T. FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis Cancer Res. 1999, 59, 4004-4011 (Pubitemid 29393569)
24. Yamori, T.; Matsunaga, A.; Sato, S.; Yamazaki, K.; Komi, A.; Ishizu, K.; Mita, I.; Edatsugi, H.; Matsuba, Y.; Takezawa, K.; Nakanishi, O.; Kohno, H.; Nakajima, Y.; Komatsu, H.; Andoh, T.; Tsuruo, T. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel Cancer Res. 1999, 59, 4042-4049 (Pubitemid 29393575)
25. Richardson, T. I.; Dodge, J. A.; Durst, G. L.; Pfeifer, L. A.; Shah, J.; Wang, Y.; Durbin, J. D.; Krishnan, V.; Norman, B. H. Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 3: synthesis of cyclopentanone and cyclohexanone intermediates for C-ring modification Bioorg. Med. Chem. Lett. 2007, 17, 4824-4828 (Pubitemid 47187700)
26. Dai, L. Z.; Shi, Y. L.; Zhao, G. L.; Shi, M. A facile synthetic route to 2 H -chromenes: reconsideration of the mechanism of the DBU-catalyzed reaction between salicylic aldehydes and ethyl 2-methylbuta-2,3-dienoate Chemistry 2007, 13, 3701-3706 (Pubitemid 46925628)